Page last updated: 2024-08-17

chlorisondamine and Atherosclerotic Parkinsonism

chlorisondamine has been researched along with Atherosclerotic Parkinsonism in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abin-Carriquiry, JA; Costa, G; Dajas, F	1

Other Studies

1 other study(ies) available for chlorisondamine and Atherosclerotic Parkinsonism

Article	Year
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain research, 2001, Jan-12, Volume: 888, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Injections, Subcutaneous; Male; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra	2001

Article

Year

Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.

Brain research, 2001, Jan-12, Volume: 888, Issue:2

Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Injections, Subcutaneous; Male; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra

2001